Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
Arrowhead Pharmaceuticals (NASDAQ:ARWR) has announced it will host a webcast and conference call on November 26, 2024, at 4:30 p.m. ET to discuss its financial results for the 2024 fiscal year ended September 30, 2024. Investors can access the live audio webcast through the Events and Presentations page on the company's website. A replay will be available approximately two hours after the call concludes. Analysts wishing to participate must register through the provided link to receive dial-in details and a personalized PIN code.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) ha annunciato che ospiterà un webcast e una conference call il 26 novembre 2024 alle 16:30 ET per discutere i propri risultati finanziari per l'anno fiscale 2024 conclusosi il 30 settembre 2024. Gli investitori possono accedere al webcast audio in diretta tramite la pagina Eventi e Presentazioni sul sito web dell'azienda. Una registrazione sarà disponibile circa due ore dopo la conclusione della chiamata. Gli analisti che desiderano partecipare devono registrarsi attraverso il link fornito per ricevere i dettagli di accesso e un codice PIN personalizzato.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) ha anunciado que llevará a cabo un webcast y una conferencia telefónica el 26 de noviembre de 2024 a las 4:30 p.m. ET para discutir sus resultados financieros del año fiscal 2024 finalizado el 30 de septiembre de 2024. Los inversores pueden acceder al webcast de audio en vivo a través de la página de Eventos y Presentaciones en el sitio web de la compañía. Una repetición estará disponible aproximadamente dos horas después de que concluya la llamada. Los analistas que deseen participar deben registrarse a través del enlace proporcionado para recibir los detalles de acceso y un código PIN personalizado.
Arrowhead Pharmaceuticals (NASDAQ:ARWR)는 2024년 11월 26일 오후 4시 30분 ET에 웹캐스트 및 컨퍼런스 콜을 개최하여 2024 회계연도(2024년 9월 30일 종료)의 재무 결과를 논의할 것이라고 발표했습니다. 투자자들은 회사 웹사이트의 이벤트 및 프레젠테이션 페이지를 통해 생중계 오디오 웹캐스트에 접속할 수 있습니다. 통화가 종료된 후 약 두 시간 후에 재생 목록이 제공됩니다. 참여를 원하는 애널리스트는 제공된 링크를 통해 등록하여 전화 접속 세부 정보와 개인 PIN 코드를 받아야 합니다.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) a annoncé qu'elle organisera un webcast et une conférence téléphonique le 26 novembre 2024 à 16 h 30 ET pour discuter de ses résultats financiers pour l'exercice fiscal 2024 clôturé le 30 septembre 2024. Les investisseurs peuvent accéder au webcast audio en direct via la page Événements et Présentations sur le site Web de l'entreprise. Une rediffusion sera disponible environ deux heures après la fin de l'appel. Les analystes souhaitant participer doivent s'enregistrer via le lien fourni pour recevoir les détails de connexion et un code PIN personnalisé.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) hat angekündigt, am 26. November 2024 um 16:30 Uhr ET ein Webcast und eine Telefonkonferenz abzuhalten, um die Finanzergebnisse für das Geschäftsjahr 2024, das am 30. September 2024 endete, zu diskutieren. Investoren können über die Seite Veranstaltungen und Präsentationen auf der Website des Unternehmens auf den Live-Audio-Webcast zugreifen. Eine Wiederholung wird etwa zwei Stunden nach Abschluss des Anrufs verfügbar sein. Analysten, die teilnehmen möchten, müssen sich über den bereitgestellten Link registrieren, um Zugangsdaten und einen personalisierten PIN-Code zu erhalten.
- None.
- None.
Webcast and Conference Call and Details
Investors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours after the conclusion of the call.
For analysts that wish to participate in the conference call, please register at https://register.vevent.com/register/BIc060a13ae8224934aac09d48abe7b2f6. Once registered, you will receive the dial-in number and a personalized PIN code that will be required to access the call.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.
For more information, please visit www.arrowheadpharma.com, or follow us on X (formerly Twitter) at @ArrowheadPharma, LinkedIn, Facebook, and Instagram. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this release except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,” “hope,” “intend,” “plan,” “project,” “could,” “estimate,” “continue,” “target,” “forecast” or “continue” or the negative of these words or other variations thereof or comparable terminology are intended to identify such forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, expectations for our product pipeline or product candidates, including anticipated regulatory submissions and clinical program results, prospects or benefits of our collaborations with other companies, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, and our research and development programs; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of numerous factors and uncertainties, including the impact of the ongoing COVID-19 pandemic on our business, the safety and efficacy of our product candidates, decisions of regulatory authorities and the timing thereof, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, the enforcement of our intellectual property rights, and the other risks and uncertainties described in our most recent Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and other documents filed with the Securities and Exchange Commission from time to time. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source: Arrowhead Pharmaceuticals, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241105476503/en/
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400
ir@arrowheadpharma.com
Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578
britchie@lifesciadvisors.com
Media:
LifeSci Communications, LLC
Kendy Guarinoni, Ph.D.
724-910-9389
kguarinoni@lifescicomms.com
Source: Arrowhead Pharmaceuticals, Inc.
FAQ
When will Arrowhead Pharmaceuticals (ARWR) report its fiscal year 2024 earnings?
How can investors access Arrowhead Pharmaceuticals' (ARWR) fiscal year 2024 earnings call?